FORWARD-LOOKING STATEMENTS

This presentation and oral statements accompanying this presentation contain forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as expected revenue, gross margin and production volume in 2019, including related growth rates, the anticipated development, scaling and commercialization of Amyris’s product pipeline and introduction of new products, including HMOs and cannabinoid ingredients, expected growth of Amyris’s Clean Beauty business, the anticipated size of the global beauty and personal care market, including categories thereof, as well as Amyris’s entry into certain of such market categories, including the timing thereof, and expectations regarding Amyris’s financial and operational results and ability to achieve its business plan in 2019 and beyond. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris’s liquidity and ability to fund operating and capital expenses, risks related to potential delays or failures in development, production and commercialization of products, risks related to Amyris’s reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.
Our Mission Is To Make The World Healthier One Molecule At A Time
We unlock biology to manufacture what comes from nature faster, better and cheaper.
A fully integrated R&D platform, purpose-built to disrupt.

- Automated Strain Engineering
- High-throughput screening
- Automated Design
- Data capture, machine learning, human intelligence
- Manufacturing
- Analytics
- Fermentation

Copyright © 2019 Amyris, Inc. All rights reserved
2008 Manual curation
Manual curation of literature
Cut and paste DNA editing

2018 Instant route-finding and DNA design
Computational atlas of metabolism
>120,000 metabolites, >140,000 reactions
High-level scripting for programming cells
We have created a new industry that is delivering best in class natural products at industrial scale.
Accelerating Disruption

From first strain to first pilot run

- 90% Lower average product development cost
- 80% Decreased average time to market
- 500% Increased productivity

Throughput 100x

Copyright © 2019 Amyris, Inc. All rights reserved
From Idea To Industrial-Scale, Making Natural Sustainable

<table>
<thead>
<tr>
<th>Step</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Engineer <strong>microbial factories</strong>&lt;br&gt;Emeryville, CA, USA (near San Francisco)&lt;br&gt;#1 Synthetic Technology Platform</td>
</tr>
<tr>
<td>2</td>
<td>Produce ingredients using our <strong>industrial fermentation technology</strong>&lt;br&gt;Brotas, Brazil CMOs&lt;br&gt;Fully integrated production of high value products</td>
</tr>
<tr>
<td>3</td>
<td>Commercialize through collaboration partners and direct to consumer&lt;br&gt;Formulate and sell own products&lt;br&gt;Proven Commercial Platform&lt;br&gt;Ingredients ➔ Consumer</td>
</tr>
</tbody>
</table>
We Are Just Starting To Make The World Healthier

[Graph showing project timelines and yields for different products, including Biofene, F&F, Cosmetic, and Art acid.]

Copyright © 2019 Amyris, Inc. All rights reserved
Market Leadership
Fastest Growing in:
1) Clean Beauty Brand
2) Clean Beauty Ingredients
3) Strategic F&F Ingredient Supplier

Industry Leading Product Pipeline
1) HMOs
2) Vitamins
3) Cannabinoids

A product marketing company powered by the world’s leading science
Our Platform is Delivering the Leading Industry Growth

<table>
<thead>
<tr>
<th>Molecules</th>
<th>‘18-’19 Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Farnesene Derivatives</td>
<td>172%</td>
</tr>
<tr>
<td>Skin Care</td>
<td>301%</td>
</tr>
<tr>
<td>Skin Care</td>
<td>163%</td>
</tr>
<tr>
<td>High Performing Polymer</td>
<td>129%</td>
</tr>
<tr>
<td><strong>Farnesene Derived</strong></td>
<td>201%</td>
</tr>
<tr>
<td>Fragrance</td>
<td>214%</td>
</tr>
<tr>
<td><strong>Fermentation</strong></td>
<td>234%</td>
</tr>
<tr>
<td>Sweetener</td>
<td>5800%</td>
</tr>
<tr>
<td>Flavor</td>
<td>2000%</td>
</tr>
<tr>
<td>Fragrance</td>
<td>422%</td>
</tr>
<tr>
<td>1st Fragrance</td>
<td>175%</td>
</tr>
<tr>
<td>Cosmetic Active</td>
<td>67%</td>
</tr>
<tr>
<td>Cosmetic Active</td>
<td>Scaling up</td>
</tr>
<tr>
<td>Fragrance</td>
<td>Scaling up</td>
</tr>
<tr>
<td>Fragrance</td>
<td>Scaling up</td>
</tr>
</tbody>
</table>

Note: 2018 Actual vs.2019 Plan Volume

**2016-2019 REVENUE CAGR**

- Ingredient Sales +61%
- Branded Product Sales +277%

Copyright © 2019 Amyris, Inc. All rights reserved
### Amyris Partners with the Leading Companies in the Industry

<table>
<thead>
<tr>
<th>Company Rank</th>
<th>Est. 2017</th>
<th>Sales USD$</th>
<th>Market Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Givaudan</td>
<td>$5,132.80</td>
<td>19.50%</td>
</tr>
<tr>
<td>2</td>
<td>Firmenich</td>
<td>$3,668.40 (est)</td>
<td>13.9% (est)</td>
</tr>
<tr>
<td>3</td>
<td>IFF</td>
<td>$3,398.70</td>
<td>12.90%</td>
</tr>
<tr>
<td>4</td>
<td>Symrise</td>
<td>$2,672.60</td>
<td>10.20%</td>
</tr>
<tr>
<td>5</td>
<td>Mane SA</td>
<td>$1,306.10</td>
<td>5.00%</td>
</tr>
<tr>
<td>6</td>
<td>Frutarom</td>
<td>$1,271.40</td>
<td>4.80%</td>
</tr>
<tr>
<td>7</td>
<td>Takasago</td>
<td>$1,185.40</td>
<td>4.50%</td>
</tr>
<tr>
<td>8</td>
<td>Sensient Flavors</td>
<td>$618.80</td>
<td>2.40%</td>
</tr>
<tr>
<td>9</td>
<td>Robertet SA</td>
<td>$570.00</td>
<td>2.20%</td>
</tr>
<tr>
<td>10</td>
<td>T. Hasegawa</td>
<td>$428.10</td>
<td>1.63%</td>
</tr>
</tbody>
</table>

**Sources:** Leffingwell & Associates article on 2013-2017 Flavor & Fragrance industry leaders. Estimates are as of Aug 2018. Also published on July ’18 edition of Perfumer & Flavorist.

---

**Notes:**
- **Results for Sensient Flavors & Fragrances excludes all non F&F items.**
- Accounting Period of July 1 to June 30
- **Accounts based on U.S. dollar values.**
- **Accounting Period of Sept. 1 to August 31 until year 2000**
- **Note - We have restated Takasago’s sales figures for 2013-2017 to eliminate certain revenue items such as non F&F fine chemicals such as pharmaceutical intermediates as well as real estate revenues.**
- **See also Note (6). F&F figures in the tables for 2000-2013 for Sensient Flavors & Fragrances.**
Molecule Profile From Launch

Molecule Customer Consumption/Sell-Through Volume

Source: consumption per value share reports and/or distributor data

Copyright © 2019 Amyris, Inc. All rights reserved
Advantaged Portfolio Delivers Strong Growth & Expanding Profitability

- Gross Margin %
  - 2017: 49%
  - 2018: 52%
  - 2019: 55%-65%

* Adjusted for loss making product sales on contracts and one time revenues

Product CAGR 98%

Copyright © 2019 Amyris, Inc. All rights reserved
Fastest Growing Clean Skin Care Brand

Fastest growing Clean Skin Care brand in North America.

Powered by Squalane.
Neossance™ Squalane Growth

Source: Aprinnova Distributor Data

Copyright © 2019 Amyris, Inc. All rights reserved
Beauty & Personal Care Market

Global Skincare market breakdown (2017, $B)

Skincare market distribution channels (2017, $B)

Beauty & personal care global market sizes by HPC category (2017, $B)

1 – Euromonitor 2017
Copyright © 2019 Amyris, Inc. All rights reserved
How We Win in Going to Market

• From one molecule, we are leading a new category in the Beauty Industry – Clean Beauty

• Driven by the most powerful ingredient sustainably sourced to disrupt the Beauty industry

• Setting the standards for consumers with one of the leading consumer brands in Clean Beauty

The first example of our business model at scale
Amyris Sweetener Is What Consumers Want

- Diabetes and obesity is rising
- Second-rate taste offerings no longer cut it
- Millennials are demanding pure and natural
- Amyris has the best tasting, most sustainable and purest natural sweetener
Upcoming purecane™ Consumer Launches

- **Brazil Launch**
  - Fall 2019

- **US Launch**
  - End of 2019

- **China Launch**
  - End of 2019
Product Pipeline – Cannabinoids, Vitamins, and HMO’s for Human Health

• Amyris is the known leader in successfully serving high-growth global markets with fermentation derived, naturally-sourced, sustainable ingredients

• Entering cannabinoids market with proven platform and ability to develop, scale and commercialize ingredients
  o Executed $300 million development, licensing and commercialization agreement with additional long-term royalty stream.

• In partnership with DSM, Amyris is moving quickly toward the commercialization of its first Human Milk Oligosaccharide (HMO) molecule, which is in the family of sugars from mother's milk. At the pace we’re moving, we'll have more than one to commercialize.
Can CBD Really Do All That?

- Heals PTSD
- Heals Brain Injury
- Cures Cancer
- Stops Epilepsy
- Lowers Blood Sugar
- Speeds Recovery From Workouts
- Lessens Arthritis Pain
- Prevents Anxiety
- Calms Dogs
- Relieves Menstrual Cramps
- Helps You Sleep

- Promotes Recovery from Opioid Addiction
- Treats Crohn’s Disease
- Slows Parkinson’s
- Reverses Depression
- Curbs Anger
- Slows Alzheimer’s Dementia
- Halts Psychosis
- Slows Parkinson’s
- Heals PTSD
- Heals Brain Injury

Source: NY Times
Concept and diagram by Paul Sahre.
Photo illustration by Jamie Chung.
Prop styling by Anna Surbatovich.

Copyright © 2019 Amyris, Inc. All rights reserved
Estimated warrant exercise potential proceeds of up to $222M subject to certain conditions.

Copyright © 2019 Amyris, Inc. All rights reserved
## Debt

<table>
<thead>
<tr>
<th>$ millions</th>
<th>Maturity</th>
<th>Rate</th>
<th>Cash/PIK</th>
<th>May-19</th>
<th>Quarterly Debt Service Including Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>6% convertible notes</td>
<td>Dec-21</td>
<td>6.00%</td>
<td>Cash/Shares</td>
<td>56.3</td>
<td>6.86</td>
</tr>
<tr>
<td>Ginkgo note</td>
<td>Oct-22</td>
<td>10.5%</td>
<td>Cash</td>
<td>12.0</td>
<td>0.32</td>
</tr>
<tr>
<td>Tranche II convertible notes</td>
<td>Jan-19</td>
<td>10.0%</td>
<td>PIK</td>
<td>4.9</td>
<td></td>
</tr>
<tr>
<td>Foris</td>
<td>Jul-21</td>
<td>14.50%</td>
<td>Cash</td>
<td>36.0</td>
<td>2.21</td>
</tr>
<tr>
<td>Foris Short Term Loan</td>
<td></td>
<td></td>
<td></td>
<td>10.0</td>
<td></td>
</tr>
<tr>
<td>DSM Loan (previously Guanfu)</td>
<td>Dec-21</td>
<td>10.0%</td>
<td>Cash</td>
<td>25.0</td>
<td>0.63</td>
</tr>
<tr>
<td>Nikko note</td>
<td>Dec-29</td>
<td>5.0%</td>
<td>Cash</td>
<td>3.0</td>
<td>0.09</td>
</tr>
<tr>
<td>Nikko Aprinnova note B</td>
<td>Aug-19</td>
<td>2.75%</td>
<td>Cash</td>
<td>1.1</td>
<td></td>
</tr>
<tr>
<td>Other loans</td>
<td>Various</td>
<td>Various</td>
<td>Cash</td>
<td>0.7</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Total Debt (ex-debt discount)</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>149.0</strong></td>
<td><strong>10.2</strong></td>
</tr>
<tr>
<td>Unamortized debt discount</td>
<td></td>
<td></td>
<td></td>
<td>TBD</td>
<td></td>
</tr>
<tr>
<td><strong>Total Debt (net of debt discount)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
World Class Board and Management

Amyris Board of Directors
• John Doerr, Executive Chairman, Kleiner Perkins Caufield & Byers
• Geoff Duyk, Managing Partner, Circularis Partners
• Philip Eykerman, EVP Strategy & MNA, Royal DSM
• Christoph Goppelsroeder, CEO of Nutrition Business, Royal DSM
• Frank Kung, Managing Partner, Vivo Capital
• Steve Mills, former CFO, Archer-Daniels-Midland (ADM)
• Carole Piwnica, Naxos Capital Partners
• Neil Williams, former CFO, Intuit
• Pat Yang, former EVP of Technical Operations, Roche-Genentech
• Lisa Qi, CEO & Founder, Daling Family Company
• Jim McCann, Chairman, 1-800-Flowers

Amyris Management*
• John Melo, President & CEO
• Eduardo Alvarez, COO
• Kathy Valiasek, CFO
• Caroline Hadfield, President of Pipette Baby Brand
• Catherine Gore, President of Biossance

*Select management of key business areas indicated
What is Our Competitive Advantage?

1) We own terpenes, terpenes are nature
   • 543 patents issued US & foreign with 297 patents pending
   • First biotech company who has engineered, scaled up and attained market leadership in:
     ▪ F&F Ingredients
     ▪ Clean Beauty
     ▪ Natural Sweetener

2) We have the only fully integrated business from target molecule to industrial production and commercialization

3) The most and fastest growing product revenue of any synthetic biology company in the world
Make good.
No compromise.™

Good for People
Good for the Planet
Good for Business

• Our ingredients are inside over $7B of consumer retail purchases

• You’ll find our ingredients in over 3,000 of the world’s leading personal care and beauty brands

• Our Biossance Skin Care Brand is the fastest growing Skin Care Brand in North America

• We have the leading product into the natural Sweetener market. We want to replace sugar & are committed to a healthier planet! We want to help reduce risk of Diabetes and Obesity....

• Most profitable product portfolio in the industry